The Role of Fibroblast Activation in Uterine Fibroid

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

35 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-01

Study Completion Date

2020-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Uterine fibroids (UFs), also called uterine leiomyomas or myomas, are steroid hormone-responsive, benign tumors of the smooth muscle compartment (myometrium) of the uterus. They are the most common neoplasm affecting women in their reproductive age. It is estimated that up to 77% of women develop UF in their life. UFs are one of the leading causes of hospitalisations for gynaecological disorders and are the most frequent reason for hysterectomy. According to relevant literature, 40%-60% of all the hysterectomies performed are due to the presence of UFs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Ultrasound Guided Microwave Ablation in the Treatment of Uterine Fibroids.

NCT07235787

Uterine Fibroids (Leiomyoma) Symptomatic Uterine Leiomyoma

NOT_YET_RECRUITING NA

Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy

NCT06325501

Myoma;Uterus

RECRUITING PHASE3

The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids

NCT00860002

Uterine Fibroids

UNKNOWN

Anatomopathological Evaluation of a New Ultrasound-guided Transuterine Vaginal Biopsy Technique in Uterine Fibromatous Disease

NCT06845982

Uterine Fibroids (UF)

RECRUITING NA

Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy

NCT03948789

Uterine Fibroids

ACTIVE_NOT_RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Uterine fibroids (UFs) are steroid hormone-responsive, benign tumors of the smooth muscle compartment (myometrium) of the uterus .They are the most common neoplasm affecting women in their reproductive age. UFs are mainly composed of fibroid cells and a significant ECM component which principally consists of fibroblasts. Previous studies on the pathogenesis of uterine UF have mainly focused on the differentiation and proliferation of fibroid cells. However, the histologic features of fibroid tissue suggest that fibroblasts may play an important role in the generation of UF.
* Fibroblast activation protein (FAP), fibroblast-specific marker, is a 95 kDa cell surface glycoprotein. It is a type II transmembrane serine protease and a member of proline-specific proteases family. Recent studies showed that the high expression of FAP is closely related to the occurrence of UF .Luo et al 2015 were the first who suggested that estrogen could stimulate fibroblast activation. In addition, they revealed that proliferative activity of fibroblast and the expression of FAP were significantly increased after estrogen stimulation. They also found that estrogen could promote the release of cytokines (TGFβ and IGF-1) and ECM components (collagen I, fibronectin, and laminin) from fibroblasts. Furthermore they found that silencing of FAP expression significantly decreased promotion effects of estrogen on TAF suggesting that FAP plays an important role in estrogen-mediated fibroblast activation.
* Autophag (eating of self) is a collection of processes that enables the cells to digest and recycle their cytoplasmic contents, such as toxic protein aggregates, disused organelles and invading microorganisms. Dysregulation in autophagy process have been recently described in many neoplasms. However the role of autophagy in the pathogenesis of UFs is still unclear and further understanding of its regulation and significance will be needed.
* The PI3K/AKT/mTOR signalling pathway is considered the main pathway involved in the initiation and regulation of autophagy. Previous studies found that reduced FAP significantly decreased the expression of phosphorylated AKT suggesting that FAP is an upstream factor modulating the PI3K/AkT. This study will be the first to study the link between fibroblast activation and autophagy in pathogenesis of UF through PI3K/AKT signaling pathway. Although several types of drugs (mostly antiproliferative agents) are available for UF treatment, none of them were introduced specifically as antifibrotic agents. Targeting such novel signaling pathway may be considered useful for future non surgical treatment of UF affecting both proliferative and fibrotic changes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Fibroid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients group

include 35 pre-menopausal women (age ˂ 50 years) enrolled to undergo hysterectomy for symptomatic UF at the women health hospitals, Assiut University.

* The protein expression of the followings markers will be estimated in tumor tissue samples:

1. Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).
2. Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.
3. Phosphorylated protein kinase B (pAKT ) by ELISA (protein level). analysis.
4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.
5. Reduced glutathione, an antioxidant marker by a colorimetric method

.

Measurement of protein expression in tissues.

Intervention Type GENETIC

The followings markers will be estimated in tissue

1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).
2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.
3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).
4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.
5. Reduced glutathione, an antioxidant marker by a colorimetric method

Control group

include 35 normal myometrial tissue samples obtained 1 cm away from the fibroid capsule from the same patients.

* The protein expression followings markers will be estimated in normal myometrial tissue samples

1. Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).
2. Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.
3. Phosphorylated protein kinase B (pAKT) by ELISA (protein level).
4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.
5. Reduced glutathione, an antioxidant marker by a colorimetric method

.

Measurement of protein expression in tissues.

Intervention Type GENETIC

The followings markers will be estimated in tissue

1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).
2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.
3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).
4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.
5. Reduced glutathione, an antioxidant marker by a colorimetric method

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Measurement of protein expression in tissues.

The followings markers will be estimated in tissue

1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).
2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis.
3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level).
4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.
5. Reduced glutathione, an antioxidant marker by a colorimetric method

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

i. Premenopausal women (age ˂ 50) with uterine fibroids who are diagnosed through clinical gynecological, ultrasound and other auxiliary examinations.

ii. Patients who exhibit a normal coagulation function.

Exclusion Criteria

* i. Patients who have a previous history of myomectomy or with ovarian malignancy and borderline tumors ii. Patients who are subsequently diagnosed with uterine adenomyosis. iii. Pregnant women. iv. Patients who receive hormonal treatment within three months before surgery. v. Patients with history of coronary artery disease, hypertension, liver cirrhosis or hematologic disorders.

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes